Literature DB >> 2771352

Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy.

J R Guy1, S Fagien, J P Donovan, M L Rubin.   

Abstract

Five patients with severe dysthyroid optic neuropathy were treated with intravenous methylprednisolone (1 g daily for 3 consecutive days). Before administration, visual acuity of the more severely affected eyes of each patient was counting fingers at 5 feet, 8/200, 20/400, 20/200, and 20/80. Immediately after completion of pulse therapy, visual acuity improved to 20/25 in four patients and 20/30 in one. Remissions were maintained with oral prednisone and external beam irradiation of the orbit. Pulse methylprednisolone therapy appears to be beneficial in the initial management of severe dysthyroid optic neuropathy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2771352     DOI: 10.1016/s0161-6420(89)32784-9

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  9 in total

1.  Contrast sensitivity and the diagnosis dysthyroid optic neuropathy.

Authors:  M P Mourits; M S Suttorp-Schulten; R O Tijssen; P Apkarian
Journal:  Doc Ophthalmol       Date:  1990 Apr-Jul       Impact factor: 2.379

2.  Efficacy of combined orbital radiation and systemic steroids in the management of Graves' orbitopathy.

Authors:  Ji Won Kim; Sun Hyup Han; Byeong Jae Son; Tyler Hyungtaek Rim; Ki Chang Keum; Jin Sook Yoon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-15       Impact factor: 3.117

3.  Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy.

Authors:  K A Ponto; T Diana; H Binder; N Matheis; S Pitz; N Pfeiffer; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2015-03-04       Impact factor: 4.256

Review 4.  A British Ophthalmological Surveillance Unit (BOSU) study into dysthyroid optic neuropathy in the United Kingdom.

Authors:  Yun Wong; Jane Dickinson; Petros Perros; Colin Dayan; Pratibha Veeramani; Daniel Morris; Barny Foot; Lucy Clarke
Journal:  Eye (Lond)       Date:  2018-06-18       Impact factor: 3.775

5.  Clinical profile and visual outcomes after treatment in patients with dysthyroid optic neuropathy.

Authors:  Chan Jeon; Jae Ho Shin; Kyung In Woo; Yoon-Duck Kim
Journal:  Korean J Ophthalmol       Date:  2012-03-22

6.  Contrast sensitivity function in Graves' ophthalmopathy and dysthyroid optic neuropathy.

Authors:  M S Suttorp-Schulten; R Tijssen; M P Mourits; P Apkarian
Journal:  Br J Ophthalmol       Date:  1993-11       Impact factor: 4.638

7.  [Management of moderate and severe dysthyroid orbitopathy: about 22 cases].

Authors:  Nadia Daldoul; Leila Knani; Faten Gatfaoui; Hechmi Mahjoub
Journal:  Pan Afr Med J       Date:  2017-08-07

8.  Diagnostic ability of Barrett's index to detect dysthyroid optic neuropathy using multidetector computed tomography.

Authors:  Mário L R Monteiro; Allan C P Gonçalves; Carla T M Silva; Janete P Moura; Carolina S Ribeiro; Eloisa M M S Gebrim
Journal:  Clinics (Sao Paulo)       Date:  2008-06       Impact factor: 2.365

9.  Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study.

Authors:  Connie M Sears; Yao Wang; Lucy A Bailey; Roger Turbin; Prem S Subramanian; Raymond Douglas; Kimberly Cockerham; Andrea L Kossler
Journal:  Am J Ophthalmol Case Rep       Date:  2021-05-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.